Pulmonx is back in focus after analysts trimmed the price target from US$6 to US$5, while keeping a model fair value estimate of US$5.17 per share unchanged. This shift reflects a mixed read on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results